POP Treatment and Management / Pelvic Organ Prolapse Companies

The POP Treatment and Management / Pelvic Organ Prolapse Market is estimated to grow from USD 0.77 billion in 2025 to USD 1.06 billion by 2030 at a CAGR of 6.6%.

POP Treatment and Management / Pelvic Organ Prolapse products are essential in treating various pelvic prolapse disorders, as they restore anatomical support and improve quality of life. The product range includes advanced solutions such as robotic-assisted systems and biological grafts, surgical products like synthetic mesh and sutures, and traditional options such as vaginal pessaries. Pelvic floor therapy devices and diagnostic and assessment tools are also needed for prolapse management and diagnosis. These products are widely accessible and used across hospitals, specialty clinics, and ambulatory surgery centers (ASCs). Adhering to clinical guidelines and regulatory standards ensures effective management of prolapse conditions and enhances patient outcomes.

Notable companies in this market include Boston Scientific Corporation (US), Coloplast Group (Denmark), Intuitive Surgical Operations, Inc. (US), CooperCompanies (US), Johnson & Johnson (US), GE HealthCare (US), Integra LifeSciences Corporation (US), B. Braun SE (Germany), and pfm medical gmbh (Germany), among others. These leading companies in the market focus on higher sales, product launches, and product approvals.

To know about the assumptions considered for the study download the pdf brochure

Boston Scientific Corporation (US)

Boston Scientific is a global medical technology company committed to advancing treatment solutions through innovation, strategic expansion, and strong R&D investments. The company has reinforced its presence in the pelvic organ prolapse (POP) segment by increasing its R&D spending and introducing advanced technologies to improve pelvic organ prolapse outcomes. In 2023, it boosted its R&D investment by USD 91 million to support a robust pipeline of new products. Boston Scientific continues to strengthen its market leadership in POP treatment with a global footprint covering over 130 countries and a strong presence across hospitals and outpatient settings.

Coloplast Group (Denmark)

Through its Interventional Urology division, Coloplast offers a comprehensive portfolio of pelvic organ prolapse (POP) treatment solutions, including synthetic mesh and biological grafts. These products are designed to support pelvic organ prolapse, focusing on safety, durability, and patient-specific needs. The company’s commitment to innovation, supported by physician training and ongoing clinical research, enhances the effectiveness and adoption of its POP solutions. By delivering high-quality surgical materials and expanding its global reach, Coloplast continues to strengthen its position as a leading provider in pelvic health and reconstruction.

Intuitive Surgical Operations, Inc. (US)

Intuitive Surgical is a global leader in robotic-assisted surgery, known for pioneering advanced solutions that transform surgical care. In the pelvic organ prolapse (POP) space, the company continues to drive innovation through its robust R&D pipeline and advanced technologies like the da Vinci robotic systems. With the recent FDA clearance of the da Vinci 5 in March 2024, Intuitive has further strengthened its leadership in minimally invasive pelvic procedures. The company’s focus on imaging, instrument control, and clinical integration supports improved surgical precision and outcomes. Through strong partnerships with physicians, hospitals, and technology providers, Intuitive promotes wider adoption of robotic surgery and addresses economic barriers with tailored acquisition models. These strategic efforts reinforce its position as a key enabler of innovation in pelvic organ prolapse.

Market Ranking

The POP Treatment and Management / Pelvic Organ Prolapse market is dominated by major players such as Boston Scientific Corporation (US), Coloplast Group (Denmark), Intuitive Surgical Operations, Inc. (US), CooperCompanies (US), and Johnson & Johnson (US). Coloplast Group (Denmark) stands out in the market through its POP Treatment and Management / Pelvic Organ Prolapse solutions and strong R&D strength, enabling it to provide efficient POP products. CooperCompanies (US) gains its market position through strategic partnerships. Boston Scientific Corporation (US) has strengthened its position with its worldwide reach and strategic acquisitions. Market competition is fueled by innovative products for POP Treatment and Management / Pelvic Organ Prolapse, as well as growing regulatory compliance requirements.

Related Reports:

POP Treatment and Management / Pelvic Organ Prolapse Market by Product (Synthetic Mesh, Sutures, Pessaries, Robotic Systems), Treatment (Surgical, PFMT), Application (Cystocele, Uterine Prolapse), End User (Hospitals, ASCs), Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com